Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid + diphtheria toxoid + acellular pertussis vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tdap is a combination vaccine designed for booster immunization against tetanus, diphtheria, and pertussis (whooping cough) in adolescents and adults. It is formulated with inactivated tetanus toxoid, a reduced dose of diphtheria toxoid, and acellular pertussis antigens (typically including pertussis toxoid, filamentous hemagglutinin, and pertactin). The reduced concentrations of diphtheria and pertussis components distinguish it from the pediatric DTaP vaccine, aiming to minimize local adverse reactions in older populations while maintaining protective immunity. The vaccine works by inducing the production of neutralizing antibodies against the toxins produced by *Clostridium tetani*, *Corynebacterium diphtheriae*, and *Bordetella pertussis*. It is routinely recommended for pregnant women to facilitate the transplacental transfer of maternal antibodies to the neonate, providing early protection against pertussis.
- Brand names
- BoostrixAdacel
- Other names
- tetanus, diphtheria, and acellular pertussis vaccineTdap vaccine
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)Diphtheria toxinFCGR2B (Fc gamma receptor IIB)
Beyond the preview
Go deeper on tetanus toxoid + diphtheria toxoid + acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid + diphtheria toxoid + acellular pertussis vaccine.